Therefore, treatment with SOC TKIs in NSCLC could have a favorable outcome for these patients, as shown by case studies of patients receiving ALK/ROS1 inhibitors [25] or Osimertinib [26]. Here, ROS1 is linked to non-small cell lung carcinoma.